Shots:
- Natera has acquired Foresight Diagnostics, adding its PhasED-Seq phased variant technology with LOD95 of 0.3ppm & detection below 0.1ppm, further enhancing Natera’s capabilities in solid tumor MRD and expanding its IP portfolio of >500 issued/pending patents
- As per the agreement, Natera completed the acquisition in an all-stock transaction incl. $275M upfront & up to $175M in earnouts tied to revenue & reimbursement-based milestones
- Integration of phased variants will strengthen Signatera performance across solid tumors, with the enhanced version of research available immediately for biopharma & academia and clinical launch expected in 2026; the deal also accelerates Natera’s expansion in lymphoma, supported by Foresight’s CLARITY MRD assay and NCCN-supported data
Ref: Natera | Image: Natera & Foresight Diagnostics | Press Release
Related News: Foresight Diagnostic & Allogene Therapeutics Extend Collaboration to Develop Minimal Residual Disease (MRD) Assay
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
